Harmony Biosciences Holdings Inc. (HRMY) News
Filter HRMY News Items
HRMY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
HRMY News Highlights
- HRMY's 30 day story count now stands at 9.
- Over the past 18 days, the trend for HRMY's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- RARE, DRUG and IH are the most mentioned tickers in articles about HRMY.
Latest HRMY News From Around the Web
Below are the latest news stories about HARMONY BIOSCIENCES HOLDINGS INC that investors may wish to consider to help them evaluate HRMY as an investment opportunity.
Short seller petitions FDA to reverse approval of Harmony Biosciences drugHarmony Biosciences' said the New York firm is "attempting to profit from driving down our stock price and deny patients’ access" to its sleep disorder therapy. |
Nike downgraded amid US wholesale pressures, China risks: 4 big analyst cutsHere is your Pro Recap of the biggest analyst cuts you may have missed since Friday: downgrades at Nike, Harmony Biosciences, Foot Locker , and Plains All American. Nike (NYSE:NKE) shares fell more than 1% pre-market today after Jefferies downgraded the company to Hold from Buy and cut its price target to $100.00 from $140.00, as reported in real-time on InvestingPro. |
HARMONY BIOSCIENCES PRESIDENT & CEO JEFFREY M. DAYNO, M.D., NAMED TO 2023 PHARMAVOICE 100 LIST OF TOP INDUSTRY LEADERSJeffrey M. Dayno, M.D., President & CEO of Harmony Biosciences, was named to the 2023 PharmaVoice 100 list for his unwavering commitment to bring clinical innovation and hope to patients living with rare neurological diseases. Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases. |
This Biotech Stock Pick Is Just Starting to Make Beautiful MusicThings have started to turn up for this midcap name. Look for these shares to end the year on an up note. |
HARMONY BIOSCIENCES TO PARTICIPATE IN 2023 CANTOR GLOBAL HEALTHCARE CONFERENCEHarmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Harmony's management team will participate in a fireside chat at the upcoming 2023 Cantor Global Healthcare Conference in New York, NY on Wednesday, September 27, 2023, at 10:20 a.m. ET. |
We Ran A Stock Scan For Earnings Growth And Harmony Biosciences Holdings (NASDAQ:HRMY) Passed With EaseIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story... |
10 Biotech Stocks with Biggest UpsideIn this article, we discuss 12 biotech stocks with biggest upside. If you want to skip our detailed discussion on the recent developments in the biotech industry, you can go directly to 5 Biotech Stocks with Biggest Upside. According to Precedence Research, the size of the biotechnology industry stood at $1.22 trillion at the end […] |
Harmony Biosciences Holdings Inc (HRMY): A Deep Dive into Its Performance PotentialUnraveling the Factors That Could Limit the Company's Future Outperformance |
HARMONY BIOSCIENCES ANNOUNCES US FOOD & DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT FOR TREATMENT OF IDIOPATHIC HYPERSOMNIAHarmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to pitolisant for the treatment of idiopathic hypersomnia (IH). |
HARMONY BIOSCIENCES REITERATES CONFIDENCE IN WAKIX® (PITOLISANT) PATENTS FOLLOWING FAVORABLE DECISION BY U.S. PATENT AND TRADEMARK OFFICE (USPTO) TO DENY PETITION FOR REEXAMINATIONHarmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today commented on the favorable decision by the U.S. Patent and Trademark Office (USPTO) to deny a Petition for Reexamination concerning a patent covering the active ingredient in WAKIX® (pitolisant). |